Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma

Clinical Biochemistry

Volumn 33, Issue 7, 2000, Pages 579-583

  Diamandis, Eleftherios P ^a,b   Yousef, George M ^a,b   Soosaipillai, Antoninus R ^a   Bunting, Peter ^b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Human kallikrein 6; Neurosin; Ovarian cancer biomarkers; Protease M; Tumor markers; Zyme

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; KALLIKREIN; KALLIKREIN 6; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

EID: 0034543474     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(00)00182-X     Document Type: Article

References (26)

1. The new human kallikrein gene family: Implications in carcinogenesis
2. Prostate specific antigen-its usefulness in clinical medicine
3. Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era
4. Prostate-specific antigen and early detection of prostate cancer
5. New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease
6. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate
7. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain
8. A novel protease homolog differentially expressed in breast and ovarian cancer
9. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain
10. New nomenclature for the human tissue kallikrein gene family
11. Molecular characterization of zyme/proteaseM/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease
12. Immunofluorometric assay of human kallikrein 6 (Zyme/Protease M/Neurosin) and preliminary clinical applications
13. Hormonal aspects of epithelial ovarian cancer: Review of epidemiological evidence
14. Recent developments in ovarian cancer screening
15. Comparison of serum immunoassays for the quantification of CA 125 antigen in serum
16. The role of CA 125 in screening for ovarian cancer
17. Serum markers as prognostic factors in epithelial ovarian cancer: An overview
18. CA 125: The past and the future
19. Combined inhibin and CA 125 assays in the detection of ovarian cancer
20. Is inhihin a serum marker for ovarian cancer?
21. Inhibin A, B and pro-alphaC in serum and peritoneal fluid in postmenopausal patients with ovarian tumors
22. Inhibin and ovarian cancer
23. OVX1 radioimmunoassay complements CA-125 for predicting presence of residual ovarian carcinoma at second-look surgical surveillance procedures
24. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection
25. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic markers